2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P5982
    PTPσ Inhibitor, ISP
    PTPσ Inhibitor, ISP can bind to recombinant human PTPs and inhibits PTPσ signaling. PTPσ Inhibitor, ISP can penetrate the membrane and relieves the chondroitin sulfate proteoglycan (CSPG)-mediated axonal sprouting inhibition in spinal cord injury model. PTPσ Inhibitor, ISP enhances remyelination in LPC-induced demyelinated spinal cord. PTPσ Inhibitor, ISP also promotes oligodendrocyte progenitor cells (OPCs) migration, maturation, remyelination, and functional recovery in animal models of Multiple Sclerosis (MS).
    PTPσ Inhibitor, ISP
  • HY-Y0135
    Tropinone 532-24-1 99.69%
    Tropinone, an alkaloid, acts as a synthetic intermediate to Atropine.
    Tropinone
  • HY-100119
    Enecadin 259525-01-4 99.71%
    Enecadin is a neuroprotective agent extracted from patent US 8623823 B2.
    Enecadin
  • HY-100122
    Bevenopran 676500-67-7 99.82%
    Bevenopran is a peripheral μ-opioid receptor antagonist.
    Bevenopran
  • HY-100143
    Pentiapine 81382-51-6 99.95%
    Pentiapine (CGS 10746) is a dopamine release inhibitor without binding to synaptic dopamine receptor sites.
    Pentiapine
  • HY-100166
    AP521 151227-08-6 98.96%
    AP521 is an agonist of human 5-HT1A receptor with an IC50 of 94 nM.
    AP521
  • HY-100243
    (+)-Norcisapride 202590-69-0 99.32%
    (+)-Norcisapride (Ticalopride) is a potent 5-HT4 agonist and a 5-HT3 antagonist. (+)-Norcisapride has activity in animals models of constipation.
    (+)-Norcisapride
  • HY-100244
    NS1652 1566-81-0 99.87%
    NS1652 is a reversible anion conductance inhibitor, blocks chloride channel, with an IC50 of 1.6 μM in human and mouse red blood cells.
    NS1652
  • HY-100275
    MK-3328 1201323-97-8 99.70%
    MK-3328 is a β-Amyloid ligand, which exhibits high binding potency with an IC50 of 10.5 nM. MK-3328 is capable of being labelled with 18F for positron emission tomography (PET) imaging.
    MK-3328
  • HY-100290
    5-HT1A modulator 1 142477-34-7
    5-HT1A modulator 1 displays very high affinities for the 5HT1A, adrenergic α1 and dopamine D2 receptor with IC50s of 2 ±0.3 nM, 10 ± 3 nM and 40 ±9 nM, respectively.
    5-HT1A modulator 1
  • HY-100376
    CPI-1189 183619-38-7 98.49%
    CPI-1189 is an orally active TNF-α release inhibitor. CPI-1189 inhibits phosphorylation of p38. CPI-1189 can inhibit apoptosis. CPI-1189 can be used in the study of HIV and neurological diseases.
    CPI-1189
  • HY-100379
    Valrocemide 92262-58-3 99.42%
    Valrocemide (TV1901) is a promising antiepileptic agent candidate that shows a broad spectrum of anticonvulsant activity.
    Valrocemide
  • HY-10043A
    gamma-secretase modulator 1 hydrochloride 2741571-83-3 99.85%
    gamma-secretase inhibitior-1 is a gamma-secretase modulator, γ-secretase inhibitior-1 is useful for Alzheimer's disease.
    gamma-secretase modulator 1 hydrochloride
  • HY-100530
    Rp-cAMPS triethylammonium salt 151837-09-1 99.53%
    Rp-cAMPS triethylammonium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS triethylammonium salt is resistant to hydrolysis by phosphodiesterases.
    Rp-cAMPS triethylammonium salt
  • HY-100616
    cis-ACBD 73550-55-7 ≥98.0%
    cis-ACBD is a potent and selective inhibitor of the high-affinity, Na+-dependent plasma membrane glutamate transporter. cis-ACBD is a glutamate reuptake inhibitor. cis-ACBD also acts as linear competitive inhibitor of the uptake of D-[3H]aspartate.
    cis-ACBD
  • HY-100646
    (E)-10-Hydroxynortriptyline maleate 74853-74-0 98%
    (E)-10-Hydroxynortriptyline maleate is a metabolite of Nortriptyline. Nortriptyline is a tricyclic antidepressant and the main active metabolite of Amitriptyline, and is used to relieve the symptoms of depression.
    (E)-10-Hydroxynortriptyline maleate
  • HY-100664
    Zopiclone N-oxide 43200-96-0 ≥98.0%
    Zopiclone N-oxide (RP 29753) is a less active metabolite of Zopiclone. Zopiclone N-oxide is also an impurity of Eszopiclone and is formed by the oxidation of Eszopiclone.
    Zopiclone N-oxide
  • HY-100667
    UBP608 2199-87-3 99.60%
    UBP608 is a potent N-Methyl-D-aspartate receptors (NMDARs) negative allosteric modulator. UBP608 has the potential for the research of neurological disorders.
    UBP608
  • HY-100686
    U93631 152273-12-6 99.85%
    U93631 is a GABAA receptor ligand of novel chemical structure with IC50 of 100 nM,and has been shown to induce a rapid, time-dependent decay of GABA-induced whole-cell Cl-currents in recombinant GABAA receptors.
    U93631
  • HY-100799
    ZAPA sulfate 371962-01-5 99.25%
    ZAPA sulfate is an agonist at low affinity GABAA-receptors. ZAPA sulfate induces membrane hyperpolarization of the Ascaris muscle cell with an EC50 of 10.3 μM.
    ZAPA sulfate
Cat. No. Product Name / Synonyms Application Reactivity